semaglutide · injectable
Zephira™
15–20% body weight reduction
Once-weekly injection proven to help people lose 15–20% of body weight in clinical trials.
- Once-weekly dosing
- Pre-filled for easy self-injection
- Clinically proven results
AdminBy invitation · Only 50 seats
An exclusive evening with 💚 Zuri Health
A private Caribbean launch introducing Zephira™ and Zuritide™, the next generation of GLP‑1 weight care, presented by Mr. Gregory Arneaud.
Saturday, 23 May 2026·5:00 PMQueen's Park Oval, Port of Spain
00
Days
00
Hours
00
Min
00
Sec
Date
Sat, 23 May 2026
Time
5:00 PM AST
Venue
Queen's Park Oval
Presenter
Mr. Gregory Arneaud
Dress
Business casual
What's launching
Two breakthrough GLP‑1 treatments, presented in one evening.
Mr. Gregory Arneaud walks you through the science, the dosing, and the patient experience behind Zephira and Zuritide, followed by a live Q&A.
tirzepatide · injectable
Zuritide™
Up to 22.5% body weight reduction
Dual-action GLP-1 for enhanced weight loss results. Up to 22.5% body weight reduction in clinical trials.
- Dual mechanism of action
- Enhanced efficacy
- Weekly dosing
Background & education
Why this evening matters for doctors, pharmacists and dietitians.
GLP‑1 (Glucagon‑Like Peptide‑1) receptor agonists mimic the natural gut hormone released in response to food. They have become the leading specialised metabolic therapy for clinical weight management and conditions such as Type 2 diabetes and obesity, and your patients are already asking about them.
Built for clinicians
Designed for doctors, pharmacists and dietitians who advise patients on metabolic care, so you get the clinical detail your patients will ask about.
Evidence, not marketing
A grounded look at the mechanism, the trial data and the real-world protocols behind GLP‑1 and dual-action therapies.
Safety & contraindications
Clear guidance on MTC/MEN 2 contraindications, monitoring and the cold-chain handling these biologics demand.
How it works
Three mechanisms, one coordinated effect on appetite and glycaemia.
01
Glucose‑dependent insulin secretion
GLP‑1 receptor agonists enhance insulin release only when blood glucose is elevated, lowering hypoglycaemia risk.
02
Glucagon suppression
They suppress glucagon, the hormone that drives hepatic glucose output and raises blood sugar.
03
Delayed gastric emptying
Food stays in the stomach longer, so patients feel fuller sooner, eat less, and report fewer cravings.
Combined with diet and exercise, GLP‑1 therapies are clinically proven to induce sustainable body weight reductions of 15–20%. Next-generation dual-action agonists targeting both GLP‑1 and GIP receptors can facilitate weight loss of up to 22.5%.
The Zuri Health formulary
Three therapies, prescribed under physician oversight.
Zephira™
semaglutide
15–20%
Once-weekly single-action GLP‑1 agonist. Sustainable body weight reduction of 15–20% in controlled trials and within Zuri Health's own protocols.
Zuritide™
tirzepatide
Up to 22.5%
Next-generation dual-action agonist targeting both GLP‑1 and GIP receptors, currently the most effective non‑surgical weight loss treatment available.
Zelvanta™
semaglutide
Cardio benefits
Another frequently prescribed GLP‑1 option offering sustainable weight loss alongside proven cardiovascular benefits.
Guaranteed lowest price
Guaranteed cheapest cost in the region. Plus, free samples available at the event.
Cold-chain handling
Both semaglutide and tirzepatide are temperature-sensitive biologics requiring vaccine-grade cold-chain storage to remain effective from dispensary to patient.
Safety & clinical oversight
Potent therapies require careful patient selection.
GLP‑1 medications carry a warning for the potential risk of thyroid C‑cell tumors. They are strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Zuri Health's program requires an initial online health history review and ongoing monitoring by a board-certified physician before any prescription is issued.
All medications dispensed through Zuri Health, including Zephira™, Zelvanta™ and Zuritide™, are FDA-approved or clinically validated, with every prescription reviewed by a board-certified provider against the patient's full medical history.
Patient story
“I've lost 45 pounds in 6 months with Zuri Health. The entire process was so easy, and my provider has been incredibly supportive throughout my journey.”
Sarah M.
Verified patient
−45 lbs
in 6 months
Agenda
A focused 45 minutes, then we stay to talk.
- 5:00 PMWelcome & arrivalDoors open. Refreshments served.
- 5:15 PMProduct presentationMr. Henry Miller introduces Zephira™ and Zuritide™.
- 5:45 PMLive Q&AAn open floor for your clinical and patient questions.
- 6:00 PMNetworking closeContinue the conversation over light bites.
Limited to 50 seats
Reserve your seat.
Your RSVP is saved instantly. Your email app will also open with a copy you can send to our team for confirmation.
RSVP deadline
Friday, 22 May 2026 · 4:00 PM
The venue
Queen's Park Oval
An iconic Caribbean setting in the heart of Port of Spain, with the Northern Range as our backdrop. Easy parking on-site.
94 Tragarete Road
Port of Spain, Trinidad and Tobago